Table 2 Correlation between PELP1 protein expression and clinicopathological variables in patients with TNBC

Age (years)

 ≤50

69

31 (44.9 %)

38 (55.1 %)

0.843

 >50

60

28 (46.7 %)

32 (53.3 %)

Tumor size (cm)^a

 ≤2

31

13 (41.9 %)

18 (58.1 %)

0.635

 >2, ≤5

74

33 (44.6 %)

41 (55.4 %)

 >5

22

12(54.5 %)

10 (45.5 %)

Lymph node stage

 negative

65

36 (55.4 %)

29 (44.6 %)

0.027

 positive

64

23 (35.9 %)

41 (64.1 %)

Grade

 G1

24

13 (54.2 %)

11 (45.8 %)

0.612

 G2

30

14 (46.7 %)

16 (53.3 %)

 G3

75

32 (42.7 %)

43 (57.3 %)

Clinical stage^a

 I

19

11 (57.9 %)

8 (42.1 %)

0.374

 II

62

29 (46.8 %)

33 (53.2 %)

 III and IV

46

18 (39.1 %)

28 (60.9 %)

Histological type

 IDC

101

45 (44.6 %)

56 (55.4 %)

0.250

 ILC

18

11 (61.1 %)

7 (38.9 %)

 Others

10

3 (30.0 %)

7 (70.0 %)

Ki-67 LI

 Low (≤14 %)

39

17 (43.6 %)

22 (56.4 %)

0.747

 High (>14 %)

90

42 (46.7 %)

48 (53.3 %)

Chemotherapy

 AC

45

22 (48.9 %)

23 (51.1 %)

0.945

 AC-T

72

32 (44.4 %)

40 (55.6 %)

 Others

10

4 (40.0 %)

6 (60.0 %)

 None

2

1 (50.0 %)

1 (50.0 %)

Radiotherapy

 No

67

30 (44.8 %)

37 (55.2 %)

0.820

 Yes

62

29 (46.8 %)

33 (53.2 %)

Cohort

 FAHHMU

49

22 (44.9 %)

27 (55.1 %)

0.820

 DLH

45

21 (46.7 %)

24 (53.5 %)

 DOGH

35

16 (45.7 %)

19 (54.3 %)